H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), emphasized the critical need for a unified global halal mark. This standard is essential to support the worldwide expansion of the halal economy, a move that will contribute to opening new markets and significantly enhance consumer confidence. Dr. Aljadhey noted that the halal sector is a vast, rapidly growing economic space, driven by rising international demand, and is poised for substantial growth in the coming period.

The Saudi Food and Drug Authority (SFDA) has signed a Memorandum of Understanding (MoU) with the Portuguese Food and Economic Safety Authority (AESA). The signing took place in the presence of the Minister of Economy and Planning, H.E. Faisal F. Alibrahim, on the sidelines of the Saudi-Portuguese Joint Commission chaired by the Ministry.

The SFDA was represented at the signing ceremony by the CEO, H.E. Dr. Hisham S. Aljadhey while the Portuguese side was represented by the Inspector General of AESA, Mr. Luís Lourenço.

The Kingdom of Saudi Arabia has added a new international achievement to its pioneering record in the food sector. The Codex Alimentarius Commission (CAC), during its 48th session held from November 10–14 at the headquarters of the Food and Agriculture Organization of the United Nations (FAO) in Rome, adopted the first international standard for fresh dates. This achievement occurred during the Kingdom’s co-chairing of the working group for international standard development.

The Saudi Food and Drug Authority (SFDA), in cooperation with the Cultural Houses “Al-Taawun Public Library”, one of initiatives under the Libraries Commission – will organize an awareness workshop under the theme “Today’s Awareness is Tomorrow’s Safety.” The event will be held on Tuesday, November 18, at the library’s headquarters in Riyadh, and aims to shed light on antimicrobial resistance (AMR) and its threat to public health.

The Saudi Food and Drug Authority (SFDA) has published a comprehensive report titled “Journey of Change and Health Transformations”, detailing its key achievements in promoting healthier dietary patterns in Saudi Arabia. The report highlighted the Authority’s ongoing commitment to enhancing public health and advancing the Quality of Life Program under Saudi Vision 2030.

To leverage modern technologies in its regulatory operations, the CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched Automation and Use of Artificial Intelligence for Food Control". The launch took place during the fourth edition of the Digital Government Forum 2025, held in Riyadh from November 5–6.

The Saudi Food and Drug Authority (SFDA) organized its Regulatory Research Day 2025 event on Monday at its headquarters in Riyadh. The event was attended by the CEO of the SFDA, H.E. Dr. Hisham S. Aljadhey, along with a number of researchers, officials, and representatives from scientific institutions.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched the National Network for Drugs and Medical Products Safety During Pregnancy and Breastfeeding on the sidelines of the SFDA's participation in the Global Health Exhibition. The Exhibition was held in Riyadh from October 27–30, with the participation of more than 2,000 entities from around the world.

The Saudi Food and Drug Authority (SFDA) yesterday, Wednesday, signed a Memorandum of Cooperation (MOC) with the Saudi Public Health Authority (Weqaya) to set an institutional framework that governs the exchange of expertise and collaboration areas between the two parties. The signing took place on the sidelines of the Global Health Exhibition 2025, which is currently being held at the Riyadh Exhibition and Convention Center under the theme “Invest in Health,” and is set to continue until October 30.

The Saudi Food and Drug Authority (SFDA) organized two specialized workshops on its Digital Health Platform as part of its participation in the Global Health Exhibition 2025, held in Riyadh under the theme “Invest in Health.” The workshops aimed to highlight leading regulatory practices in clinical trials for medical devices and in digital and emerging health technologies.